Virtual Clinical Trials Market

Decentralized Clinical Trials Market / Virtual Clinical Trials Market (2nd Edition), Till 2035: Distribution by Mode of Clinical Trial (Hybrid Clinical Trials and Fully Virtual Clinical Trials), Type of Therapeutic Area (Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Clinical Trial Phase (Phase I, Phase II, Phase III and Phase IV), Company Size (Small, Mid-sized and Large), End Users (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes , Medical Device Industries and Other End Users) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America): Industry Trends and Global Forecasts

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    421

  • Pages
    480

  • View Count
    20925

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH
2.1. Healthcare Policies
2.2. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Traditional Clinical Trials versus Decentralized Clinical Trials
5.3. Need for Decentralized Clinical Trials
5.3.1. Increasing Trial Costs and Complexity
5.3.2. Evolving Regulatory Standards
5.3.3. Patient Recruitment / Retention-related Challenges
5.3.4. Inefficient Data Handling

5.4. Decentralized Clinical Trials
5.4.1. Modes of Decentralized Clinical Trials
5.4.1.1. Fully Virtual Decentralized Clinical Trials
5.4.1.2. Hybrid Decentralized Clinical Trials

5.5. Applications of Decentralized Clinical Trials
5.6. Emerging Trends in Clinical Drug Development
5.6.1. Innovative Trial Designs
5.6.2. Real-world Evidence
5.6.3. Patient-centricity
5.6.4. Big Data Analytics
5.6.5. Blockchain Technology

5.7. Challenges Associated with Decentralized Clinical Trials
5.8. Future Perspectives

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Decentralized Clinical Trials Service Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters (Region)
6.2.4. Analysis by Location of Headquarters (Country)
6.2.5. Analysis by Company Size and Location of Headquarters (Region)
6.2.6. Analysis by Key Offering
6.2.7. Analysis by Compliance
6.2.8. Analysis by Mode of Decentralized Clinical Trial
6.2.9. Analysis by Type of Capability
6.2.10. Analysis by Mode of Decentralized Clinical Trial and Type of Capability
6.2.11. Analysis by Therapeutic Area
6.2.12. Analysis by Mode of Decentralized Clinical Trial and Therapeutic Area
6.2.13. Analysis by Trial Phase

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Detailed Company Profiles of Key Players
7.2.1. Fortrea
7.2.1.1. Company Overview
7.2.1.2. Decentralized Clinical Trial Offerings
7.2.1.3. Recent Developments and Future Outlook

7.2.2. IQVIA
7.2.2.1. Company Overview
7.2.2.2. Financial Information
7.2.1.2. Decentralized Clinical Trial Offerings
7.2.1.3. Recent Developments and Future Outlook

7.2.3. KORE Wireless
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Decentralized Clinical Trial Offerings
7.2.3.4. Recent Developments and Future Outlook

7.2.4. Labcorp
7.2.4.1. Company Overview
7.2.4.2. Financial Information
7.2.4.3. Decentralized Clinical Trial Offerings
7.2.4.4. Recent Developments and Future Outlook

7.2.5. Medpace
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Decentralized Clinical Trial Offerings
7.2.5.4. Recent Developments and Future Outlook

7.2.6. Parexel
7.2.6.1. Company Overview
7.2.6.2. Decentralized Clinical Trial Offerings
7.2.6.3. Recent Developments and Future Outlook

7.2.7. PPD
7.2.7.1. Company Overview
7.2.7.2. Financial Information
7.2.7.3. Decentralized Clinical Trial Offerings
7.2.7.4. Recent Developments and Future Outlook

7.2.8. Syneos Health
7.2.8.1. Company Overview
7.2.8.2. Financial Information
7.2.8.3. Decentralized Clinical Trial Offerings
7.2.8.4. Recent Developments and Future Outlook

7.2.9. Signant Health
7.2.9.1. Company Overview
7.2.9.2. Decentralized Clinical Trial Offerings
7.2.9.3. Recent Developments and Future Outlook

7.2.10. Veeva
7.2.10.1. Company Overview
7.2.10.2. Financial Information
7.2.10.3. Decentralized Clinical Trial Offerings
7.2.10.4. Recent Developments and Future Outlook

7.2.11. Cambridge Cognition
7.2.11.1. Company Overview
7.2.11.2. Financial Information
7.2.11.3. Decentralized Clinical Trial Offerings
7.2.11.4. Recent Developments and Future Outlook

7.2.12. Medidata Solutions
7.2.12.1. Company Overview
7.2.12.2. Financial Information
7.2.12.3. Decentralized Clinical Trial Offerings
7.2.12.4. Recent Developments and Future Outlook

7.2.13. PanAmerican Clinical Research
7.2.13.1. Company Overview
7.2.13.2. Decentralized Clinical Trial Offerings
7.2.13.3. Recent Developments and Future Outlook

7.2.14. Science 37
7.2.14.1. Company Overview
7.2.14.2. Financial Information
7.2.14.3. Decentralized Clinical Trial Offerings
7.2.14.4. Recent Developments and Future Outlook

7.3. Short Profiles of Other Prominent Players
7.3.1. Aardex
7.3.1.1. Company Overview
7.3.1.2. Decentralized Clinical Trial Offerings

7.3.2. CareShare
7.3.2.1. Company Overview
7.3.2.2. Decentralized Clinical Trial Offerings

7.3.3. Clariness
7.3.3.1. Company Overview
7.3.3.2. Decentralized Clinical Trial Offerings

7.3.4. Cliniv
7.3.4.1. Company Overview
7.3.4.2. Decentralized Clinical Trial Offerings

7.3.5. Clinscience
7.3.5.1. Company Overview
7.3.5.2. Decentralized Clinical Trial Offerings

7.3.6. CMIC
7.3.6.1. Company Overview
7.3.6.2. Decentralized Clinical Trial Offerings

7.3.7. DynamiQ Health
7.3.7.1. Company Overview
7.3.7.2. Decentralized Clinical Trial Offerings

7.3.8. Emovis
7.3.8.1. Company Overview
7.3.8.2. Decentralized Clinical Trial Offerings

7.3.9. Ergomed
7.3.9.1. Company Overview
7.3.9.2. Decentralized Clinical Trial Offerings

7.3.10. Flatworld Solutions
7.3.10.1. Company Overview
7.3.10.2. Decentralized Clinical Trial Offerings

7.3.11. Gsap
7.3.11.1. Company Overview
7.3.11.2. Decentralized Clinical Trial Offerings

7.3.13. Hexaware Technologies
7.3.13.1. Company Overview
7.3.13.2. Decentralized Clinical Trial Offerings

7.3.14. Huma
7.3.14.1. Company Overview
7.3.14.2. Decentralized Clinical Trial Offerings

7.3.15. ICON
7.3.15.1. Company Overview
7.3.15.2. Decentralized Clinical Trial Offerings

7.3.16. Kayentis
7.3.16.1. Company Overview
7.3.16.2. Decentralized Clinical Trial Offerings

7.3.17. Tata Consultancy Services
7.3.17.1. Company Overview
7.3.17.2. Decentralized Clinical Trial Offerings

7.3.18. Viedoc
7.3.18.1. Company Overview
7.3.18.2. Decentralized Clinical Trial Offerings

7.3.19. WeGuide
7.3.19.1. Company Overview
7.3.19.2. Decentralized Clinical Trial Offerings

7.3.20. Wren Healthcare
7.3.20.1. Company Overview
7.3.20.2. Decentralized Clinical Trial Offerings

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies based in North America
8.5. Competitiveness Analysis: Companies based in Europe
8.6. Competitiveness Analysis: Companies based in Asia-Pacific and Rest of the World

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Decentralized Clinical Trials
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Number of Patients Enrolled
9.3.3. Analysis by Trial Phase
9.3.4. Analysis by Trial Registration Year and Trial Phase
9.3.5. Analysis by Patients Enrolled and Trial Phase
9.3.6. Analysis by Trial Status
9.3.7. Analysis by Trial Registration Year and Trial Status
9.3.8. Analysis by Target Patient Population
9.3.9. Analysis by Patient Gender
9.3.10. Analysis by Therapeutic Area
9.3.11. Analysis by Type of Sponsor / Collaborator
9.3.12. Word Cloud Analysis: Emerging Focus Areas

9.3.13. Analysis by Study Design
9.3.13.1. Analysis by Type of Patient Allocation Model Used
9.3.13.2. Analysis by Type of Trial Masking Adopted
9.3.13.3. Analysis by Type of Intervention
9.3.13.4. Analysis by Trial Purpose

9.3.14. Most Active Players: Analysis by Number of Clinical Trials

9.3.15. Analysis by Geography
9.3.15.1. Analysis of Clinical Trials by Geography
9.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
9.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Decentralized Clinical Trials: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Partner
10.3.5. Analysis by Year of Partnership and Type of Partner
10.3.6. Analysis by Type of Partnership and Type of Partner
10.3.7. Analysis by Type of Capability
10.3.8. Analysis by Type of Partnership and Type of Capability
10.3.9. Most Active Players: Analysis by Number of Partnerships

10.3.10. Analysis by Geography
10.3.10.1. Local and International Agreements
10.3.10.2. Intracontinental and Intercontinental Agreements

11. FUNDING AND INVESTMENTS
11.1. Chapter Overview
11.2. Funding Models
11.3. Decentralized Clinical Trials: Funding and Investments
11.3.1. Analysis by Year of Funding
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Year and Type of Funding
11.3.5. Analysis by Type of Funding and Amount Invested
11.3.6. Analysis by Geography
11.3.8. Most Active Players: Analysis by Number of Funding Instances
11.3.9. Most Active Players: Analysis by Amount Raised
11.3.10. Leading Investors: Analysis by Number of Funding Instances

11.4. Concluding Remarks

12. CASE STUDY: DECENTRALIZED CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA COMPANIES
12.1. Chapter Overview
12.2. Decentralized Clinical Trial-related Initiatives of Big Pharma Companies
12.2.1. Pfizer
12.2.1.1. Decentralized Clinical Trial-related Initiatives
12.2.1.2. Future Perspective

12.2.2. Amgen
12.2.2.1. Decentralized Clinical Trial-related Initiatives
12.2.2.2. Future Perspective

12.2.3. AstraZeneca
12.2.3.1. Decentralized Clinical Trial-related Initiatives
12.2.3.2. Future Perspective

12.2.4. GlaxoSmithKline
12.2.4.1. Decentralized Clinical Trial-related Initiatives
12.2.4.2. Future Perspective

12.2.5. Johnson & Johnson
12.2.5.1. Decentralized Clinical Trial-related Initiatives
12.2.5.2. Future Perspective

12.2.6. Novartis
12.2.6.1. Decentralized Clinical Trial-related Initiatives
12.2.6.2. Future Perspective

12.2.7. Sanofi
12.2.7.1. Decentralized Clinical Trial-related Initiatives
12.2.7.2. Future Perspective

13. CASE STUDY: TRADITIONAL VERSUS DECENTRALIZED CLINICAL TRIALS
13.1. Chapter Overview
13.2. Comparison between Traditional and Decentralized Clinical Trials
13.3. Key Attributes of Decentralized Clinical Trials
13.4. Decentralized Operating Models
13.5. Concluding Remarks

14. CASE STUDY: COVID-19 IMPACT
14.1. Chapter Overview
14.2. Impact of COVID-19 on Clinical Trials
14.3. Impact of COVID-19 on Future Opportunity for Decentralized Clinical Trial Companies

15. COST SAVING ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Overall Cost Saving Potential of Decentralized Clinical Trials, 2023-2035
15.3.1. Cost Saving Potential: Distribution by Key Geographical Regions, 2023 and 2035
15.3.1.1. Cost Saving Potential in North America, 2023-2035
15.3.1.1.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.1.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.1.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.1.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035

15.3.1.2. Cost Saving Potential in Europe, 2023-2035
15.3.1.2.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.2.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.2.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.2.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035

15.3.1.3. Cost Saving Potential in Asia-Pacific, 2023-2035
15.3.1.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.3.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035

15.3.1.4. Cost Saving Potential in Middle East and North Africa, 2023-2035
15.3.1.4.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.4.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.4.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.4.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035

15.3.1.5. Cost Saving Potential in Latin America, 2023-2035
15.3.1.5.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
15.3.1.5.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
15.3.1.5.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
15.3.1.5.4. Cost Saving Potential in Phase IV Clinical Trials, 2023-2035

15.4. Conclusion

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL DECENTRALIZED CLINICAL TRIALS MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Decentralized Clinical Trials Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario Analysis
17.3.1.2. Optimistic Scenario Analysis

17.4. Key Market Segmentations
17.5. Dynamic Dashboards

18. DECENTRALIZED CLINICAL TRIALS MARKET, BY MODE OF DECENTRALIZED CLINICAL TRIAL
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Decentralized Clinical Trials Market: Distribution by Mode of Decentralized Clinical Trial, 2023 and 2035
18.4. Hybrid Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Fully Virtual Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Data Triangulation and Validation

19. DECENTRALIZED CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Decentralized Clinical Trials Market: Distribution by Therapeutic Area, 2023 and 2035
19.4. Cardiovascular Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.8. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.9. Respiratory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.10. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.11. Data Triangulation and Validation

20. DECENTRALIZED CLINICAL TRIALS MARKET, BY TRIAL PHASE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Decentralized Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035
20.4. Phase I: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.5. Phase II: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.6. Phase III: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Phase IV: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.8. Data Triangulation and Validation

21. DECENTRALIZED CLINICAL TRIALS MARKET, BY COMPANY SIZE
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Decentralized Clinical Trials Market: Distribution by Company Size, 2023 and 2035
21.4. Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.5. Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.6. Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.7. Data Triangulation and Validation

22. DECENTRALIZED CLINICAL TRIALS MARKET, BY END-USER
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Decentralized Clinical Trials Market: Distribution by End-user, 2023 and 2035
22.4. Pharmaceutical and Biotechnology Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.5. Academic and Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.6. Medical Device Industries: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.7. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.8. Data Triangulation and Validation

23. DECENTRALIZED CLINICAL TRIALS MARKET, BY KEY GEOGRAPHICAL REGION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Decentralized Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035
23.4. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.5. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.6. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.7. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.8. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.9. Data Triangulation and Validation

24. DECENTRALIZED CLINICAL TRIALS SERVICES MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Decentralized Clinical Trials Services Market, Historical Trends (2018-2035) and Forecasted Estimates (2023-2035)
24.3.1. Decentralized Clinical Trials Services Market, 2023 and 2035: Distribution by Mode of Clinical Trials
24.3.1.1. Decentralized Clinical Trials Services Market for Hybrid Clinical Trials: Forecasted Estimates (2023-2035)
24.3.1.2. Decentralized Clinical Trials Services Market for Fully Virtual Clinical Trials, Forecasted Estimates (2023-2035)

24.3.2. Decentralized Clinical Trials Services Market: Distribution by Therapeutic Area, 2023 and 2035
24.3.2.1. Decentralized Clinical Trials Services Market for Neurological Disorders: Forecasted Estimates (2023-2035)
24.3.2.2. Decentralized Clinical Trials Services Market for Metabolic Disorders: Forecasted Estimates (2023-2035)
24.3.2.3. Decentralized Clinical Trials Services Market for Cardiovascular Disorders: Forecasted Estimates (2023-2035)
24.3.2.4. Decentralized Clinical Trials Services Market for Respiratory Disorders, Forecasted Estimates (2023-2035)
24.3.2.5. Decentralized Clinical Trials Services Market for Infectious Diseases: Forecasted Estimates (2023-2035)
24.3.2.6. Decentralized Clinical Trials Services Market for Oncological Disorders: Forecasted Estimates (2023-2035)
24.3.2.7. Decentralized Clinical Trials Services Market for Other Disorders: Forecasted Estimates (2023-2035)

24.3.3. Decentralized Clinical Trials Services Market: Distribution by Clinical Trial Phase, 2023 and 2035
24.3.3.1. Decentralized Clinical Trials Services Market for Phase I: Forecasted Estimates (2023-2035)
24.3.3.2. Decentralized Clinical Trials Services Market for Phase II: Forecasted Estimates (2023-2035)
24.3.3.3. Decentralized Clinical Trials Services Market for Phase III: Forecasted Estimates (2023-2035)
24.3.3.4. Decentralized Clinical Trials Services Market for Phase IV: Forecasted Estimates (2023-2035)

24.3.4. Decentralized Clinical Trials Services Market: Distribution by Company Size, 2023 and 2035
24.3.4.1. Decentralized Clinical Trials Services Market for Small Companies: Forecasted Estimates (2023-2035)
24.3.4.2. Decentralized Clinical Trials Services Market for Mid-sized Companies Forecasted Estimates (2023-2035)
24.3.4.3. Decentralized Clinical Trials Services Market for Large Companies: Forecasted Estimates (2023-2035)

24.3.5. Decentralized Clinical Trials Services Market: Distribution by End-users, 2023 and 2035
24.3.5.1. Decentralized Clinical Trials Services Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
24.3.5.2. Decentralized Clinical Trials Services Market for Research and Academic Institutes, Forecasted Estimates (2023-2035)
24.3.5.3. Decentralized Clinical Trials Services Market for Medical Device Industry: Forecasted Estimates (2023-2035)
24.3.5.4. Decentralized Clinical Trials Services Market for Other End-users, Forecasted Estimates (2023-2035)

24.3.6. Decentralized Clinical Trials Services Market: Distribution by Key Geographical Regions, 2023 and 2035
24.3.6.1. Decentralized Clinical Trials Services Market in North America: Forecasted Estimates (2023-2035)
24.3.6.2. Decentralized Clinical Trials Services Market in Europe: Forecasted Estimates (2023-2035)
24.3.6.3. Decentralized Clinical Trials Services Market in Asia-Pacific: Forecasted Estimates (2023-2035)
24.3.6.4. Decentralized Clinical Trials Services Market in Middle East and North Africa: Forecasted Estimates (2023-2035)
24.3.6.5. Decentralized Clinical Trials Services Market in Latin America: Forecasted Estimates (2023-2035)

25. CONCLUSION

26. EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. Company A
26.2.1. Interview Transcript (Chief Executive Officer and Founder)

26.3. Company B
26.3.1. Interview Transcript (Chief Executive Officer and Chairman)

26.4. Company C
26.4.1. Interview Transcript (Chief Executive Officer)

26.5. Company D
26.5.1. Interview Transcript (Chief Innovation Officer and President)

26.6. Company E
26.6.1. Interview Transcript (Chief Commercial Officer, Chief Delivery Officer, Chief Technology Officer, Head of Marketing

26.7. Company F
26.7.1. Interview Transcript (Chief Strategy Officer)

26.8. Company G
26.8.1. Interview Transcript (Executive Director)

26.9. Company H
26.9.1. Interview Transcript (Senior Manager Business Development)

26.10. Company I
26.10.1. Interview Transcript (Director Business Development)

26.11. Company J
26.11.1. Interview Transcript (Head of Operations)

26.12. Company K
26.12.1. Interview Transcript (Senior Business Development Director)

26.13. Company L
26.13.1. Interview Transcript (Business Development Manager)

26.14. Company L
26.14.1. Interview Transcript (President and Chief Executive Officer)

27. APPENDIX 1: TABULATED DATA

28. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trials Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investments
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Traditional Clinical Trials versus Decentralized Clinical Trials
Figure 5.2 Existing Constraints in Clinical Research
Figure 5.3 Applications of Decentralized Clinical Trials
Figure 5.4 Difference between Umbrella and Basket Clinical Trial Designs
Figure 5.5 Process of Generating Evidence from Real World Data
Figure 5.6 Patient-centric Approach to Clinical Trials
Figure 5.7 Role of Big Data in Clinical Research
Figure 6.1 Decentralized Clinical Trials Service Providers: Distribution by Year of Establishment
Figure 6.2 Decentralized Clinical Trials Service Providers: Distribution by Company Size
Figure 6.3 Decentralized Clinical Trials Service Providers: Distribution by Location of Headquarters (Region)
Figure 6.4 Decentralized Clinical Trials Service Providers: Distribution by Location of Headquarters (Country)
Figure 6.5 Decentralized Clinical Trials Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.6 Decentralized Clinical Trials Service Providers: Distribution by Key Offering
Figure 6.7 Decentralized Clinical Trials Service Providers: Distribution by Compliance
Figure 6.8 Decentralized Clinical Trials Service Providers: Distribution by Mode of Decentralized Clinical Trial
Figure 6.9 Decentralized Clinical Trials Service Providers: Distribution by Type of Capability
Figure 6.10 Decentralized Clinical Trials Service Providers: Distribution by Mode of Decentralized Clinical Trial and Type of Capability
Figure 6.11 Decentralized Clinical Trials Service Providers: Distribution by Therapeutic Area
Figure 6.12 Decentralized Clinical Trials Service Providers: Distribution by Mode of Decentralized Clinical Trial and Therapeutic Area
Figure 6.13 Decentralized Clinical Trials Service Providers: Distribution by Trial Phase
Figure 7.1 IQVIA: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.2 KORE Wireless: Annual Revenues, FY 2018-H1 FY 2023 (USD Million)
Figure 7.3 Labcorp: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.4 Medpace: Annual Revenues, FY 2018-H1 FY 2023 (USD Million)
Figure 7.5 PPD: Annual Revenues, FY 2018-9M FY 2021 (USD Billion)
Figure 7.6 Syneos Health: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.7 Veeva: Annual Revenues, FY 2018-Q1 FY 2023 (USD Million)
Figure 7.8 Cambridge Cognition: Annual Revenues, FY 2018- FY 2022 (GBP Million)
Figure 7.9 Dassault Systèmes (Parent Company of Medidata Solutions): Annual Revenues, FY 2018- H1 FY 2023 (EUR Billion)
Figure 7.10 Science 37: Annual Revenues, FY 2020-H1 FY 2023 (USD Million)
Figure 8.1 Company Competitiveness Analysis: Companies based in North America (I/III)
Figure 8.2 Company Competitiveness Analysis: Companies based in North America (II/III)
Figure 8.3 Company Competitiveness Analysis: Companies based in North America (III/III)
Figure 8.4 Company Competitiveness Analysis: Companies based in Europe
Figure 8.5 Company Competitiveness Analysis: Companies based in Asia-Pacific and Rest of the World
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Registration Year (Pre-2015-2023)
Figure 9.2 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year (Pre-20015-2023)
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase (Pre-2007-2023)
Figure 9.5 Clinical Trial Analysis: Distribution by Patient Enrolled and Trial Phase
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status (Pre-2015-2023)
Figure 9.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 9.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 9.10 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 9.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 9.12 Word Cloud Analysis: Emerging Focus Areas
Figure 9.13 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 9.14 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Figure 9.15 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 9.16 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 9.17 Most Active Players: Distribution by Number of Clinical Trials
Figure 9.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 9.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 9.20 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, 2018-2023
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Capability
Figure 10.8 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Capability
Figure 10.9 Most Active Players: Distribution by Number of Partnerships
Figure 10.10 Partnerships and Collaborations: Local and International Agreements
Figure 10.11 Partnerships and Collaborations: Intracontinental Agreements and Intercontinental Agreements
Figure 11.1 Funding and Investments: Cumulative Year-wise Trend, 2018-2023
Figure 11.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 11.3 Funding and Investments: Distribution by Type of Funding
Figure 11.4 Funding and Investments: Distribution by Year and Type of Funding
Figure 11.5 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Figure 11.6 Funding and Investments: Distribution by Geography (Region)
Figure 11.7 Funding and Investments: Distribution by Geography (Country)
Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
Figure 11.9 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 11.10 Leading Investors: Distribution by Number of Funding Instances
Figure 11.11 Funding and Investments Summary (USD Million)
Figure 12.1 Decentralized Clinical Trial-related Initiatives of Big Pharma Companies: Timeline of Events
Figure 13.1 Key Attributes of Decentralized Clinical Trials
Figure 14.1 COVID-19 Impact on Clinical Trials
Figure 15.1 Overall Cost Saving Potential of Decentralized Clinical Trials, 2023-2035 (USD Million)
Figure 15.2 Cost Saving Potential: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 15.3 Cost Saving Potential: Phase-wise Distribution in North America, 2023 and 2035 (USD Million)
Figure 15.4 Cost Saving Potential in North America for Phase I, 2023- 2035 (USD Million)
Figure 15.5 Cost Saving Potential in North America for Phase II, 2023- 2035 (USD Million)
Figure 15.6 Cost Saving Potential in North America for Phase III, 2023- 2035 (USD Million)
Figure 15.7 Cost Saving Potential in North America for Phase IV, 2023- 2035 (USD Million)
Figure 15.8 Cost Saving Potential: Phase-wise Distribution in Europe, 2023 and 2035 (USD Million)
Figure 15.9 Cost Saving Potential in Europe for Phase I, 2023- 2035 (USD Million)
Figure 15.10 Cost Saving Potential in Europe for Phase II, 2023- 2035 (USD Million)
Figure 15.11 Cost Saving Potential in Europe for Phase III, 2023- 2035 (USD Million)
Figure 15.12 Cost Saving Potential in Europe for Phase IV, 2023- 2035 (USD Million)
Figure 15.13 Cost Saving Potential: Phase-wise Distribution in Asia-Pacific, 2023 and 2035 (USD Million)
Figure 15.14 Cost Saving Potential in Asia-Pacific for Phase I, 2023- 2035 (USD Million)
Figure 15.15 Cost Saving Potential in Asia-Pacific for Phase II, 2023- 2035 (USD Million)
Figure 15.16 Cost Saving Potential in Asia-Pacific for Phase III, 2023- 2035 (USD Million)
Figure 15.17 Cost Saving Potential in Asia-Pacific for Phase IV, 2023- 2035 (USD Million)
Figure 15.18 Cost Saving Potential: Phase-wise Distribution in Middle East and North Africa, 2023 and 2035 (USD Million)
Figure 15.19 Cost Saving Potential in Middle East and North Africa for Phase I, 2023- 2035 (USD Million)
Figure 15.20 Cost Saving Potential in Middle East and North Africa for Phase II, 2023- 2035 (USD Million)
Figure 15.21 Cost Saving Potential in Middle East and North Africa for Phase III, 2023- 2035 (USD Million)
Figure 15.22 Cost Saving Potential in Middle East and North Africa for Phase IV, 2023- 2035 (USD Million)
Figure 15.23 Cost Saving Potential: Phase-wise Distribution in Latin America, 2023 and 2035 (USD Million)
Figure 15.24 Cost Saving Potential in Latin America for Phase I, 2023- 2035 (USD Million)
Figure 15.25 Cost Saving Potential in Latin America for Phase II, 2023- 2035 (USD Million)
Figure 15.26 Cost Saving Potential in Latin America for Phase III, 2023- 2035 (USD Million)
Figure 15.27 Cost Saving Potential in Latin America for Phase IV, 2023- 2035 (USD Million)
Figure 16.1 Market Drivers
Figure 16.2 Market Restraints
Figure 16.3 Market Opportunities
Figure 16.4 Market Challenges
Figure 17.1 Global Decentralized Clinical Trials Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 17.2 Global Decentralized Clinical Trials Market, 2023-2035: Conservative Scenario (USD Million)
Figure 17.3 Global Decentralized Clinical Trials Market, 2023-2035: Optimistic Scenario (USD Million)
Figure 17.4 Dynamic Dashboard
Figure 18.1 Decentralized Clinical Trials Market: Distribution by Mode of Decentralized Clinical Trial, 2023 and 2035 (USD Million)
Figure 18.2 Decentralized Clinical Trials Market for Hybrid Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 18.3 Decentralized Clinical Trials Market for Fully Virtual Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.1 Decentralized Clinical Trials Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 19.2 Decentralized Clinical Trials Market for Cardiovascular Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.3 Decentralized Clinical Trials Market for Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.4 Decentralized Clinical Trials Market for Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.5 Decentralized Clinical Trials Market for Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.6 Decentralized Clinical Trials Market for Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.7 Decentralized Clinical Trials Market for Respiratory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.8 Decentralized Clinical Trials Market for Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.1 Decentralized Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035 (USD Million)
Figure 20.2 Decentralized Clinical Trials Market for Phase I: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.3 Decentralized Clinical Trials Market for Phase II: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.4 Decentralized Clinical Trials Market for Phase III: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.5 Decentralized Clinical Trials Market for Phase IV: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.1 Decentralized Clinical Trials Market: Distribution by Company Size, 2023 and 2035 (USD Million)
Figure 21.2 Decentralized Clinical Trials Market for Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.3 Decentralized Clinical Trials Market for Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.4 Decentralized Clinical Trials Market for Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.1 Decentralized Clinical Trials Market: Distribution by End-user, 2023 and 2035 (USD Million)
Figure 22.2 Decentralized Clinical Trials Market for Pharmaceutical and Biotechnology Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.3 Decentralized Clinical Trials Market for Academic and Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.4 Decentralized Clinical Trials Market for Medical Device Industry: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.5 Decentralized Clinical Trials Market for Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.1 Decentralized Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 23.2 Decentralized Clinical Trials Market in North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.3 Decentralized Clinical Trials Market in Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.4 Decentralized Clinical Trials Market in Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.5 Decentralized Clinical Trials Market in Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.6 Decentralized Clinical Trials Market in Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 24.1 Global Decentralized Clinical Trials Services Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.2 Decentralized Clinical Trials Services Market: Distribution by Mode of Decentralized Clinical Trial, 2023 and 2035
Figure 24.3 Decentralized Clinical Trials Services Market for Hybrid Clinical Trials, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.4 Decentralized Clinical Trials Services Market for Fully Virtual Clinical Trials, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.5 Decentralized Clinical Trials Services Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 24.6 Decentralized Clinical Trials Services Market for Neurological Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.7 Decentralized Clinical Trials Services Market for Metabolic Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.8 Decentralized Clinical Trials Services Market for Cardiovascular Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.9 Decentralized Clinical Trials Services Market for Respiratory Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.10 Decentralized Clinical Trials Services Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.11 Decentralized Clinical Trials Services Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.12 Decentralized Clinical Trials Services Market for Other Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.13 Decentralized Clinical Trials Services Market: Distribution by Clinical Trial Phase, 2023 and 2035
Figure 24.14 Decentralized Clinical Trials Services Market for Phase I, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.15 Decentralized Clinical Trials Services Market for Phase II, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.16 Decentralized Clinical Trials Services Market for Phase III, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.17 Decentralized Clinical Trials Services Market for Phase IV, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.18 Decentralized Clinical Trials Services Market: Distribution by Company Size, 2023 and 2035
Figure 24.19 Decentralized Clinical Trials Services Market for Small Companies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.20 Decentralized Clinical Trials Services Market for Mid-sized companies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.21 Decentralized Clinical Trials Services Market for Large Companies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.22 Decentralized Clinical Trials Services Market: Distribution by End-user, 2023 and 2035
Figure 24.23 Decentralized Clinical Trials Services Market for Pharmaceutical and Biotechnology Companies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.24 Decentralized Clinical Trials Services Market for Research and Academic Institutes, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.25 Decentralized Clinical Trials Services Market for Medical Device Industry, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.26 Decentralized Clinical Trials Services Market for Other End-users, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.27 Decentralized Clinical Trials Services Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 24.28 Decentralized Clinical Trials Services Market in North America, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.29 Decentralized Clinical Trials Services Market in Europe, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.30 Decentralized Clinical Trials Services Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.31 Decentralized Clinical Trials Services Market in Middle East and North Africa, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.32 Decentralized Clinical Trials Services Market in Latin America, Forecasted Estimates (2023-2035) (USD Billion)
Figure 25.1 Conclusion: Market Landscape
Figure 25.2 Conclusion: Clinical Trials Analysis
Figure 25.3 Conclusion: Partnerships and Collaborations
Figure 25.4 Conclusion: Funding and Investments
Figure 25.5 Conclusion: Market Forecast and Opportunity Analysis

List Of Tables

Table 6.1 Decentralized Clinical Trials Service Providers: Information on Year of Establishment, Company Size, and Location of Headquarters
Table 6.2 Decentralized Clinical Trials Service Providers: Information on Key Offering, Compliance, Mode of Decentralized Clinical Trial and Type of Capability
Table 6.3 Decentralized Clinical Trials Service Providers: Information on Therapeutic Area and Trial Phase
Table 7.1 Decentralized Clinical Trials: List of Companies Profiled
Table 7.2 Fortrea: Company Snapshot
Table 7.3 Fortrea: Decentralized Clinical Trial Offerings
Table 7.4 IQVIA: Company Snapshot
Table 7.5 IQVIA: Decentralized Clinical Trial Offerings
Table 7.6 IQVIA: Recent Developments and Future Outlook
Table 7.7 KORE Wireless: Company Snapshot
Table 7.8 KORE Wireless: Decentralized Clinical Trial Offerings
Table 7.9 KORE Wireless: Recent Developments and Future Outlook
Table 7.10 Labcorp: Company Snapshot
Table 7.11 Labcorp: Decentralized Clinical Trial Offerings
Table 7.12 Labcorp: Recent Developments and Future Outlook
Table 7.13 Medpace: Company Snapshot
Table 7.14 Medpace: Decentralized Clinical Trial Offerings
Table 7.15 Parexel: Company Snapshot
Table 7.16 Parexel: Decentralized Clinical Trial Offerings
Table 7.17 Parexel: Recent Developments and Future Outlook
Table 7.18 PPD: Company Snapshot
Table 7.19 PPD: Decentralized Clinical Trial Offerings
Table 7.20 Syneos Health: Company Snapshot
Table 7.21 Syneos Health: Decentralized Clinical Trial Offerings
Table 7.22 Syneos Health: Recent Developments and Future Outlook
Table 7.23 Signant Health: Company Snapshot
Table 7.24 Signant Health: Decentralized Clinical Trial Offerings
Table 7.25 Signant Health: Recent Developments and Future Outlook
Table 7.26 Veeva: Company Snapshot
Table 7.27 Veeva: Decentralized Clinical Trial Offerings
Table 7.28 Veeva: Recent Developments and Future Outlook
Table 7.29 Cambridge Cognition: Company Snapshot
Table 7.30 Cambridge Cognition: Decentralized Clinical Trial Offerings
Table 7.31 Cambridge Cognition: Recent Developments and Future Outlook
Table 7.32 Medidata Solutions: Company Snapshot
Table 7.33 Medidata Solutions: Decentralized Clinical Trial Offerings
Table 7.34 Medidata Solutions: Recent Developments and Future Outlook
Table 7.35 PanAmerican Clinical Research: Company Snapshot
Table 7.36 PanAmerican Clinical Research: Decentralized Clinical Trial Offerings
Table 7.37 Science 37: Company Snapshot
Table 7.38 Science 37: Decentralized Clinical Trial Offerings
Table 7.39 Science 37: Recent Developments and Future Outlook
Table 7.40 Aardex: Company Snapshot
Table 7.41 Aardex: Decentralized Clinical Trial Offerings
Table 7.42 CareShare: Company Snapshot
Table 7.43 CareShare: Decentralized Clinical Trial Offerings
Table 7.44 Clariness: Company Snapshot
Table 7.45 Clariness: Decentralized Clinical Trial Offerings
Table 7.46 Cliniv: Company Snapshot
Table 7.47 Cliniv: Decentralized Clinical Trial Offerings
Table 7.48 Clinscience: Company Snapshot
Table 7.49 Clinscience: Decentralized Clinical Trial Offerings
Table 7.50 CMIC: Company Snapshot
Table 7.51 CMIC: Decentralized Clinical Trial Offerings
Table 7.52 DynamiQ Health: Company Snapshot
Table 7.53 DynamiQ Health: Decentralized Clinical Trial Offerings
Table 7.54 Emovis: Company Snapshot
Table 7.55 Emovis: Decentralized Clinical Trial Offerings
Table 7.56 Ergomed: Company Snapshot
Table 7.57 Ergomed: Decentralized Clinical Trial Offerings
Table 7.58 Flatworld Solutions: Company Snapshot
Table 7.59 Flatworld Solutions: Decentralized Clinical Trial Offerings
Table 7.60 Gsap: Company Snapshot
Table 7.61 Gsap: Decentralized Clinical Trial Offerings
Table 7.62 Hexaware Technologies: Company Snapshot
Table 7.63 Hexaware Technologies: Decentralized Clinical Trial Offerings
Table 7.64 Huma: Company Snapshot
Table 7.65 Huma: Decentralized Clinical Trial Offerings
Table 7.66 ICON: Company Snapshot
Table 7.67 ICON: Decentralized Clinical Trial Offerings
Table 7.68 Kayentis: Company Snapshot
Table 7.69 Kayentis: Decentralized Clinical Trial Offerings
Table 7.70 Tata Consultancy Services: Company Snapshot
Table 7.71 Tata Consultancy Services: Decentralized Clinical Trial Offerings
Table 7.72 Viedoc: Company Snapshot
Table 7.73 Viedoc: Decentralized Clinical Trial Offerings
Table 7.74 WeGuide: Company Snapshot
Table 7.75 WeGuide: Decentralized Clinical Trial Offerings
Table 7.76 Wren Healthcare: Company Snapshot
Table 7.77 Wren Healthacare: Decentralized Clinical Trial Offerings
Table 10.80 Decentralized Clinical Trials: List of Partnerships and Collaborations, 2018-2023
Table 11.81 Decentralized Clinical Trials: List of Funding and Investments, 2018-2023
Table 12.1 Decentralized Clinical Trials-related Initiatives of Big Pharma Companies
Table 12.2 Decentralized Clinical Trials Sponsored by Big Pharma Companies
Table 13.1 Comparison between Traditional Clinical Trials and Decentralized Clinical Trials
Table 25.1 Company A: Company Snapshot
Table 25.2 Company B: Company Snapshot
Table 25.3 Company C: Company Snapshot
Table 25.4 Company D: Company Snapshot
Table 25.5 Company E: Company Snapshot
Table 25.6 FineMeCure: Company Snapshot
Table 25.7 MedPoint Digital: Company Snapshot
Table 25.8 RegAsk: Company Snapshot
Table 25.9 Science37: Company Snapshot
Table 25.10 TrialX: Company Snapshot
Table 25.11 WeGuide: Company Snapshot
Table 25.12 Woodley Trial Solutions: Company Snapshot
Table 25.13 EmpiraMed: Company Snapshot
Table 27.1 Decentralized Clinical Trials Service Providers: Distribution by Year of Establishment
Table 27.2 Decentralized Clinical Trials Service Providers: Distribution by Company Size
Table 27.3 Decentralized Clinical Trials Service Providers: Distribution by Location of Headquarters (Region)
Table 27.4 Decentralized Clinical Trials Service Providers: Distribution by Location of Headquarters (Country)
Table 27.5 Decentralized Clinical Trials Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 27.6 Decentralized Clinical Trials Service Providers: Distribution by Key Offering
Table 27.7 Decentralized Clinical Trials Service Providers: Distribution by Compliance
Table 27.8 Decentralized Clinical Trials Service Providers: Distribution by Mode of Decentralized Clinical Trial
Table 27.9 Decentralized Clinical Trials Service Providers: Distribution by Type of Capability
Table 27.10 Decentralized Clinical Trials Service Providers: Distribution by Mode of Decentralized Clinical Trial and Type of Capability
Table 27.11 Decentralized Clinical Trials Service Providers: Distribution by Therapeutic Area
Table 27.12 Decentralized Clinical Trials Service Providers: Distribution by Mode of Decentralized Clinical Trial and Therapeutic Area
Table 27.13 Decentralized Clinical Trials Service Providers: Distribution by Trial Phase
Table 27.14 IQVIA: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 27.15 KORE Wireless: Annual Revenues, FY 2018-H1 FY 2023 (USD Million)
Table 27.16 Labcorp: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 27.17 Medpace: Annual Revenues, FY 2018-H1 FY 2023 (USD Million)
Table 27.18 PPD: Annual Revenues, FY 2018-9M FY 2021 (USD Billion)
Table 27.19 Syneos Health: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 27.20 Veeva: Annual Revenues, FY 2018-Q1 FY 2023 (USD Million)
Table 27.21 Cambridge Cognition: Annual Revenues, FY 2018- FY 2022 (GBP Million)
Table 27.22 Dassault Systèmes (Parent Company of Medidata Solutions): Annual Revenues, FY 2018- H1 FY 2023 (EUR Billion)
Table 27.23 Science 37: Annual Revenues, FY 2020-H1 FY 2023 (USD Million)
Table 27.24 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Registration Year (Pre-2015-2023)
Table 27.25 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year (Pre-20015–2023)
Table 27.26 Clinical Trial Analysis: Distribution by Trial Phase
Table 27.27 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase (Pre-2007–2023)
Table 27.28 Clinical Trial Analysis: Distribution by Patient Enrolled and Trial Phase
Table 27.29 Clinical Trial Analysis: Distribution by Trial Status
Table 27.30 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status (Pre-2015–2023)
Table 27.31 Clinical Trial Analysis: Distribution by Target Patient Population
Table 27.32 Clinical Trial Analysis: Distribution by Patient Gender
Table 27.33 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 27.34 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 27.35 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Table 27.36 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Table 27.37 Clinical Trial Analysis: Distribution by Type of Intervention
Table 27.38 Clinical Trial Analysis: Distribution by Trial Purpose
Table 27.39 Most Active Players: Distribution by Number of Clinical Trials
Table 27.40 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 27.41 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 27.42 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 27.43 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
Table 27.44 Partnerships and Collaborations: Distribution by Type of Partnership
Table 27.45 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
Table 27.46 Partnerships and Collaborations: Distribution by Type of Partner
Table 27.47 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, 2018-2023
Table 27.48 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 27.49 Partnerships and Collaborations: Distribution by Type of Capability
Table 27.50 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Capability
Table 27.51 Most Active Players: Distribution by Number of Partnerships
Table 27.52 Partnerships and Collaborations: Local and International Agreements
Table 27.53 Partnerships and Collaborations: Intracontinental Agreements and Intercontinental Agreements
Table 27.54 Funding and Investments: Cumulative Year-wise Trend, 2018-2023
Table 27.55 Funding and Investments: Distribution by Amount Invested (USD Million)
Table 27.56 Funding and Investments: Distribution by Type of Funding
Table 27.57 Funding and Investments: Distribution by Year and Type of Funding
Table 27.58 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Table 27.59 Funding and Investments: Distribution by Geography (Region)
Table 27.60 Funding and Investments: Distribution by Geography (Country)
Table 27.61 Most Active Players: Distribution by Number of Funding Instances
Table 27.62 Most Active Players: Distribution by Amount Raised (USD Million)
Table 27.63 Leading Investors: Distribution by Number of Funding Instances
Table 27.64 Overall Cost Saving Potential of Decentralized Clinical Trials, 2023-2035 (USD Million)
Table 27.65 Cost Saving Potential: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 27.66 Cost Saving Potential: Phase-wise Distribution in North America, 2023 and 2035 (USD Million)
Table 27.67 Cost Saving Potential in North America for Phase I, 2023- 2035 (USD Million)
Table 27.68 Cost Saving Potential in North America for Phase II, 2023- 2035 (USD Million)
Table 27.69 Cost Saving Potential in North America for Phase III, 2023- 2035 (USD Million)
Table 27.70 Cost Saving Potential in North America for Phase IV, 2023- 2035 (USD Million)
Table 27.71 Cost Saving Potential: Phase-wise Distribution in Europe, 2023 and 2035 (USD Million)
Table 27.72 Cost Saving Potential in Europe for Phase I, 2023- 2035 (USD Million)
Table 27.73 Cost Saving Potential in Europe for Phase II, 2023- 2035 (USD Million)
Table 27.74 Cost Saving Potential in Europe for Phase III, 2023- 2035 (USD Million)
Table 27.75 Cost Saving Potential in Europe for Phase IV, 2023- 2035 (USD Million)
Table 27.76 Cost Saving Potential: Phase-wise Distribution in Asia-Pacific, 2023 and 2035 (USD Million)
Table 27.77 Cost Saving Potential in Asia-Pacific for Phase I, 2023- 2035 (USD Million)
Table 27.78 Cost Saving Potential in Asia-Pacific for Phase II, 2023- 2035 (USD Million)
Table 27.79 Cost Saving Potential in Asia-Pacific for Phase III, 2023- 2035 (USD Million)
Table 27.80 Cost Saving Potential in Asia-Pacific for Phase IV, 2023- 2035 (USD Million)
Table 27.81 Cost Saving Potential: Phase-wise Distribution in Middle East and North Africa, 2023 and 2035 (USD Million)
Table 27.82 Cost Saving Potential in Middle East and North Africa for Phase I, 2023- 2035 (USD Million)
Table 27.83 Cost Saving Potential in Middle East and North Africa for Phase II, 2023- 2035 (USD Million)
Table 27.84 Cost Saving Potential in Middle East and North Africa for Phase III, 2023- 2035 (USD Million)
Table 27.85 Cost Saving Potential in Middle East and North Africa for Phase IV, 2023- 2035 (USD Million)
Table 27.86 Cost Saving Potential: Phase-wise Distribution in Latin America, 2023 and 2035 (USD Million)
Table 27.87 Cost Saving Potential in Latin America for Phase I, 2023- 2035 (USD Million)
Table 27.88 Cost Saving Potential in Latin America for Phase II, 2023- 2035 (USD Million)
Table 27.89 Cost Saving Potential in Latin America for Phase III, 2023- 2035 (USD Million)
Table 27.90 Cost Saving Potential in Latin America for Phase IV, 2023- 2035 (USD Million)
Table 27.91 Global Decentralized Clinical Trials Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 27.92 Global Decentralized Clinical Trials Market, 2023-2035: Conservative Scenario (USD Million)
Table 27.93 Global Decentralized Clinical Trials Market, 2023-2035: Optimistic Scenario (USD Million)
Table 27.94 Decentralized Clinical Trials Market: Distribution by Mode of Decentralized Clinical Trial, 2023 and 2035 (USD Million)
Table 27.95 Decentralized Clinical Trials Market for Hybrid Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.96 Decentralized Clinical Trials Market for Fully Virtual Clinical Trials: Historical Trends (2018-2022) and Forecasted Estimates, Conservative, Base and Optimistic Scenarios (2023-2035) (USD Million)
Table 27.97 Decentralized Clinical Trials Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Table 27.98 Decentralized Clinical Trials Market for Cardiovascular Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.99 Decentralized Clinical Trials Market for Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.100 Decentralized Clinical Trials Market for Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.101 Decentralized Clinical Trials Market for Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.102 Decentralized Clinical Trials Market for Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.103 Decentralized Clinical Trials Market for Respiratory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.104 Decentralized Clinical Trials Market for Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.105 Decentralized Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035 (USD Million)
Table 27.106 Decentralized Clinical Trials Market for Phase I: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.107 Decentralized Clinical Trials Market for Phase II: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.108 Decentralized Clinical Trials Market for Phase III: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.109 Decentralized Clinical Trials Market for Phase IV: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.110 Decentralized Clinical Trials Market: Distribution by Company Size, 2023 and 2035 (USD Million)
Table 27.111 Decentralized Clinical Trials Market for Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.112 Decentralized Clinical Trials Market for Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.113 Decentralized Clinical Trials Market for Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.114 Decentralized Clinical Trials Market: Distribution by End-user, 2023 and 2035 (USD Million)
Table 27.115 Decentralized Clinical Trials Market for Pharmaceutical and Biotechnology Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.116 Decentralized Clinical Trials Market for Academic and Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.117 Decentralized Clinical Trials Market for Medical Device Industry: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.118 Decentralized Clinical Trials Market for Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.119 Decentralized Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 27.120 Decentralized Clinical Trials Market in North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.121 Decentralized Clinical Trials Market in Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.122 Decentralized Clinical Trials Market in Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.123 Decentralized Clinical Trials Market in Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.124 Decentralized Clinical Trials Market in Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.125 Global Decentralized Clinical Trials Services Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 27.126 Decentralized Clinical Trials Services Market: Distribution by Mode of Decentralized Clinical Trial, 2023 and 2035
Table 27.127 Decentralized Clinical Trials Services Market for Hybrid Clinical Trials, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.128 Decentralized Clinical Trials Services Market for Fully Virtual Clinical Trials, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.129 Decentralized Clinical Trials Services Market: Distribution by Therapeutic Area, 2023 and 2035
Table 27.130 Decentralized Clinical Trials Services Market for Neurological Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.131 Decentralized Clinical Trials Services Market for Metabolic Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.132 Decentralized Clinical Trials Services Market for Cardiovascular Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.133 Decentralized Clinical Trials Services Market for Respiratory Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.134 Decentralized Clinical Trials Services Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.135 Decentralized Clinical Trials Services Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.136 Decentralized Clinical Trials Services Market for Other Disorders, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.137 Decentralized Clinical Trials Services Market: Distribution by Clinical Trial Phase, 2023 and 2035
Table 27.138 Decentralized Clinical Trials Services Market for Phase I, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.139 Decentralized Clinical Trials Services Market for Phase II, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.140 Decentralized Clinical Trials Services Market for Phase III, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.141 Decentralized Clinical Trials Services Market for Phase IV, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.142 Decentralized Clinical Trials Services Market: Distribution by Company Size, 2023 and 2035
Table 27.143 Decentralized Clinical Trials Services Market for Small Companies, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.144 Decentralized Clinical Trials Services Market for Mid-sized companies, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.145 Decentralized Clinical Trials Services Market for Large Companies, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.146 Decentralized Clinical Trials Services Market: Distribution by End-user, 2023 and 2035
Table 27.147 Decentralized Clinical Trials Services Market for Pharmaceutical and Biotechnology Companies, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.148 Decentralized Clinical Trials Services Market for Research and Academic Institutes, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.149 Decentralized Clinical Trials Services Market for Medical Device Industry, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.150 Decentralized Clinical Trials Services Market for Other End-users, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.151 Decentralized Clinical Trials Services Market: Distribution by Key Geographical Regions, 2023 and 2035
Table 27.152 Decentralized Clinical Trials Services Market in North America, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.153 Decentralized Clinical Trials Services Market in Europe, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.154 Decentralized Clinical Trials Services Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.155 Decentralized Clinical Trials Services Market in Middle East and North Africa, Forecasted Estimates (2023-2035) (USD Billion)
Table 27.156 Decentralized Clinical Trials Services Market in Latin America, Forecasted Estimates (2023-2035) (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 1nHealth
  2. 3H Medi Solution
  3. AARDEX Group
  4. AbbVie
  5. Accelmed Growth Partners
  6. Acclinate
  7. Acrew Capital
  8. ActiGraph
  9. Advanced Clinical
  10. Advarra
  11. Afortiori Development
  12. AiCure
  13. Aixial
  14. Albion Capital
  15. AlbionVC
  16. Alcanza Clinical Research
  17. Alcedis
  18. AliveCor
  19. AllianceBernstein (AB)
  20. Allucent
  21. Almac
  22. Amazon Web Services
  23. Amgen
  24. Andaman7
  25. Anju Software
  26. Annex Clinical
  27. Aparito
  28. Aperio Clinical Outcomes
  29. Apex Mobile Clinical Research
  30. Aptar
  31. ArisGlobal
  32. Arsenal Capital Partners
  33. Asahi Kasei
  34. Asia Green Fund
  35. assisTek
  36. Astorg
  37. AstraZeneca
  38. ATCOR Medical
  39. Athyrium Capital Management
  40. Athyrium Capital Management
  41. Atlantic General Hospital
  42. Atlantic Research Group
  43. AutoCruitment
  44. Avantor
  45. AzadMedica
  46. B Capital Group
  47. Baron Capital
  48. Bayer
  49. BBK Worldwide
  50. BDC Capital
  51. Bee Partners
  52. Beedie Capital
  53. BEKHealth
  54. Bezyl
  55. Biobeat
  56. Bioclinica
  57. BioIntelliSense
  58. Biorasi
  59. Black Opal Ventures
  60. Blackstone Growth
  61. Boehringer Ingelheim
  62. Bold Capital Partners
  63. Boston Clinical Research Institute
  64. Boulder Ventures
  65. BoxGroup
  66. Bpifrance
  67. BroadOak Capital Partners
  68. Brook Byers
  69. Business Mobility Partners (BMP)
  70. Byers Capital
  71. CAIMED
  72. Cambridge Cognition
  73. Canary Advisors
  74. Cancer Hospital, Chinese Academy of Medical Sciences
  75. Capgemini
  76. Care Access
  77. Care Angel
  78. care.ai
  79. CareShare
  80. Castor
  81. Centre for Innovative Technology
  82. cerascreen
  83. Chimera Investments
  84. ChroniSense Medical
  85. Circuit Clinical
  86. Clara Health
  87. Clariness
  88. Clario
  89. ClearDATA
  90. Click Therapeutics
  91. ClinCapture
  92. ClinChoice
  93. Clinical Ink
  94. Clinical Site Services
  95. Clinical Trials Transformation Initiative (CTTI)
  96. CliniMed LifeSciences
  97. Cliniv Health Tech
  98. ClinOne
  99. Clinscience
  100. Cloudbyz
  101. Cmed Technology
  102. CMIC
  103. Cofounders Capital
  104. Cogstate
  105. ConcertAI
  106. ConsilX
  107. Cquentia
  108. Crucial Data Solutions
  109. CU Healthcare Innovation Fund
  110. Curavit
  111. Curebase
  112. CureClick
  113. Current Health
  114. CVS Health
  115. Dassault Systemes
  116. Datacubed Health
  117. Datatrak
  118. Datavant
  119. Dedalus
  120. Dedalus Group
  121. Deep 6 AI
  122. Define Ventures
  123. Delve Health
  124. Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
  125. Digital Artefacts (DA)
  126. DNV
  127. Dr. William H. Joyce Family Office
  128. DSG
  129. DynamiQ Health
  130. eClinicalHealth
  131. Eight Roads Ventures
  132. Eldridge
  133. Elements Health Ventures
  134. Eli Lily
  135. Emovis (Acquired by Futuremeds)
  136. Empatica
  137. EmpiraMed
  138. endpoint Clinical
  139. epHealth
  140. EQT
  141. Equicare Health
  142. Ergomed
  143. ERT
  144. European Investment Fund
  145. European Investment Fund
  146. EVERSANA
  147. Every Cure
  148. Evidation
  149. Extens
  150. FindMeCure
  151. Firma Clinical Research
  152. First Trust Capital Partners
  153. Flashpoint
  154. Flatworld Solutions
  155. Florence Healthcare
  156. Fortrea (Spin-off of LabCorp)
  157. Foundation Medicine
  158. F-Prime Capital
  159. Fulcrum Equity Partners
  160. gBETA Medtech
  161. GE Ventures
  162. General Catalyst
  163. GGV Capital
  164. GI Alliance
  165. GI Partners
  166. GlaxoSmithKline
  167. Globant
  168. Goldman Sachs Asset Management
  169. Growth & Transition Capital
  170. Gsap
  171. GSR Ventures
  172. H Clinical
  173. Halloran
  174. Halo Health Systems
  175. Hambrecht Ducera Growth Ventures
  176. HAT Fund
  177. Hawthorne Effect
  178. Healint
  179. Health Wizz
  180. HealthCore
  181. HealthVerity
  182. HEALTHY VENTURES
  183. Hexaware Technologies
  184. Hitachi
  185. Houston Methodist
  186. Huma
  187. HumanFirst
  188. Hyfe
  189. ICON
  190. IMA Group
  191. iMedrix
  192. IMP Clinical Supply Services
  193. Infiuss Health
  194. INKEF Capital
  195. Insight Partners
  196. Instituto Brasil de Pesquisa Clínica
  197. Integrative Genomics Viewer (IGV)
  198. Intel
  199. Interlace Health (Formerly known as FormFast)
  200. InventisBio
  201. iPlato Healthcare
  202. IQVIA
  203. ixlayer
  204. Janssen Pharmaceuticals
  205. JDRF
  206. Jeeva Informatics Solutions
  207. JLL Partners
  208. Johnson & Johnson
  209. Kaiser Permanente
  210. Kayentis
  211. Khosla Ventures
  212. KiwiTech
  213. Koch Industries
  214. Koneksa Health
  215. KORE Wireless
  216. Labcorp
  217. Lateral Capital
  218. LBO France
  219. LEO Pharma
  220. Leonard Green & Partners
  221. Leukemia & Lymphoma Society
  222. LifeLab
  223. Lightship
  224. Linical
  225. LLR Partners
  226. Loftware
  227. Lokavant
  228. LRVHealth
  229. M&B Sciences
  230. Marken
  231. Matrix Capital Management
  232. Matrix Clinical Trials
  233. Matrix Medical Network
  234. Maverick Ventures
  235. MBX Capital
  236. MC10
  237. McKesson Ventures
  238. Medable
  239. Medgate
  240. Medical Research Network
  241. Medicover Integrated Clinical Services (Formerly known as Synevo Central Labs)
  242. Medidata (Acquired by Dassault Systemes)
  243. MedNet
  244. Medocity
  245. Medpace
  246. Medpoint Digital
  247. Medrio
  248. Merck Global Health Innovation Fund
  249. Meru Health
  250. MMC Ventures
  251. MMS
  252. Monograph Capital
  253. Montrium
  254. MRN
  255. Mural Health
  256. Myia Health
  257. Narrow Gauge Ventures
  258. National Science Foundation
  259. Neoteryx
  260. Neoteryx
  261. Nestle Health Science
  262. NextEquity Partners
  263. Nicola Wealth
  264. Nordic Capital
  265. Northlane Capital Partners
  266. Northpond Ventures
  267. Nova Scotia Health Authority
  268. Novartis
  269. Novo Holdings
  270. Novotech
  271. N-SIDE
  272. NuvoAir
  273. ObvioHealth
  274. Odyssey Investment Partners
  275. OMERS Growth Equity
  276. OmniComm Systems
  277. OncoBay Clinical
  278. OpenClinica
  279. Oracle
  280. Osage Venture Partners (OVP)
  281. OSF HealthCare
  282. P5 Health Ventures
  283. Palisades Growth Capital
  284. PanAmerican Clinical Research
  285. Par Equity
  286. Paraxel
  287. Pattern Health
  288. Persephone Biosciences
  289. Pfizer
  290. PHARMASEAL
  291. PharPoint Research
  292. PHASTAR
  293. Pivotal Clinical Trials
  294. Portamedic
  295. Positive Sum
  296. PPD
  297. PPMD
  298. PRA Health Sciences
  299. PRIMR
  300. Privis Health
  301. PROMETRIKA
  302. Propeller Health
  303. ProPharma
  304. ProRelix Research
  305. Publicis Health
  306. RA Capital Management
  307. RARE-X
  308. RedHill Biopharma
  309. RegASK
  310. Reown Health 
  311. Research Professionals
  312. Reveles
  313. Ripple Science
  314. Rock Health
  315. Rocket Internet
  316. Royal Group
  317. Royal Street Ventures
  318. Samsung
  319. Sanguine Biosciences
  320. Sanofi
  321. Sanofi Ventures
  322. Sapphire Ventures
  323. SAS
  324. Science 37
  325. S-Clinica
  326. Scottish Investment Bank
  327. Section 32
  328. Shanghai Mental Health Center
  329. Shanghai Xinhua Pharmaceutical Technology
  330. Sharecare
  331. Shawbrook Bank
  332. SignalFire
  333. Signant Health
  334. Signify Health
  335. SIMON IoT
  336. Singtel Innov8
  337. Sixth Street
  338. snapIoT
  339. SoftServe
  340. SPRIM Global Investments
  341. Spring Mountain Capital
  342. SpringRock Ventures
  343. Sterling IRB
  344. Sterling National Bank
  345. Sterling Partners
  346. Suvoda
  347. SV Health
  348. Syapse
  349. Symphony Clinical Research
  350. SymphonyAI
  351. Syneos Health
  352. Synexus
  353. Tabatabai Investment Partners
  354. Takeda Ventures
  355. Tasso
  356. Tata Consultancy Services
  357. Techstars
  358. Teckro
  359. The Launch Place
  360. Thermo Fisher Scientific
  361. THREAD
  362. Tiger Global
  363. TKS 1
  364. TPG Capital
  365. Trajan
  366. Travera
  367. Trialbee
  368. Triall
  369. Trials@Home
  370. TrialX
  371. Triangle Tweener Fund
  372. TriNetX
  373. Triumph Research Intelligence
  374. Truist Bank
  375. TruLab
  376. Tryl
  377. Two Sigma Ventures
  378. UC Davis Health
  379. UCB
  380. UM6P Ventures
  381. uMotif
  382. Unilever
  383. United BioSource
  384. University of Birmingham
  385. University of Bristol
  386. University of Manchester
  387. University of Pittsburgh Clinical and Translational Science Institute (CTSI)
  388. UPS Healthcare
  389. Vault Health
  390. Veeva Systems
  391. Velocity Structured Solutions
  392. VeraSci
  393. Veristat
  394. Verustat
  395. Vial
  396. Viedoc
  397. Virginia Innovation Partnership
  398. VirTrial
  399. Virtual Clinical
  400. VisualDx
  401. Vivalink
  402. Vsee
  403. Walgreens
  404. Water Street
  405. Water Street Healthcare Partners
  406. Waterline Ventures
  407. WCG
  408. Wealth Club
  409. WeGuide
  410. Western Technology Investment (WTI)
  411. WindRose Health
  412. Withings Health Solutions
  413. Woodley Trial Solutions
  414. Woodline Partners
  415. World Innovation Lab
  416. Wren Healthcare
  417. xCures
  418. Xfund
  419. Xperiome
  420. YPrime

The complete list of companies and organizations included in the report is available on request.

Source 1: http://www.sagitec.com/blog/recruiting-for-clinical-trials-doesnt-have-to-be-a-challenge
Source 2: https://www.pharmafocusasia.com/clinical-trials/virtual-world-digital-clinical-trials

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com